It does not mean that this problem is unequivocally resolved and not requires further basic research and clinical observations on the effects of ACE inhibitors and AT1R blockers (and other drugs, e.g., statins) in patients infected with SARS-CoV2 and COVID-19. The gene discussed is AGTR1; the disease is COVID-19.